Pharmaceutical Executive
Pharmaceutical Executive-04-01-2021
Volume: 41
Issue: 4
Pharmaceutical Executive-03-01-2021
Volume: 41
Issue: 3
Pharmaceutical Executive-02-01-2021
Volume: 41
Issue: 2
Pharmaceutical Executive-01-01-2021
Volume: 41
Issue: 1
Pharmaceutical Executive-12-01-2020
Volume: 40
Issue: 12
Pharmaceutical Executive-11-01-2020
Volume: 40
Issue: 11
Pharmaceutical Executive-10-01-2020
Volume: 40
Issue: 10
Pharmaceutical Executive-09-01-2020
Volume: 40
Issue: 9
Pharmaceutical Executive-08-01-2020
Volume: 40
Issue: 8
Pharmaceutical Executive-07-01-2020
Volume: 40
Issue: 7
Pharmaceutical Executive-06-01-2020
Volume: 40
Issue: 6
Pharmaceutical Executive-05-01-2020
Volume: 40
Issue: 5
Pharmaceutical Executive-04-01-2020
Volume: 40
Issue: 4
Pharmaceutical Executive-03-01-2020
Volume: 40
Issue: 3
Pharmaceutical Executive-02-01-2020
Volume: 40
Issue: 2
Pharmaceutical Executive-01-01-2020
Volume: 40
Issue: 1
Pharmaceutical Executive-12-01-2019
Volume: 39
Issue: 12
Pharmaceutical Executive-11-01-2019
Volume: 39
Issue: 11
Pharmaceutical Executive-10-01-2019
Volume: 39
Issue: 10
Pharmaceutical Executive-09-01-2019
Volume: 39
Issue: 9
Pharmaceutical Executive-08-01-2019
Volume: 39
Issue: 8
Pharmaceutical Executive-07-01-2019
Volume: 39
Issue: 7
Pharmaceutical Executive-06-01-2019
Volume: 39
Issue: 6
Pharmaceutical Executive-05-01-2019
Volume: 39
Issue: 5
Pharmaceutical Executive-04-01-2019
Volume: 39
Issue: 4
Pharmaceutical Executive-03-01-2019
Volume: 39
Issue: 3
Pharmaceutical Executive-02-01-2019
Volume: 39
Issue: 2
Pharmaceutical Executive-01-01-2019
Volume: 39
Issue: 1
Pharmaceutical Executive-12-01-2018
Volume: 38
Issue: 12
Pharmaceutical Executive-11-01-2018
Volume: 38
Issue: 11
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
The Importance of Reframing COVID-19 as a Preventable Event
3
FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer
4
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
5